v3.26.3
SEGMENT INFORMATION - Schedule of Income Before Income Taxes Regarding the Company's Reportable Segments (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Financial information regarding the Company's reportable segments        
Net Sales $ 1,019,119 $ 961,131 $ 3,028,495 $ 2,814,445
Cost of Sales (exclusive of depreciation and amortization): 646,196 598,046 1,938,146 1,747,931
Selling, Research & Development and Administrative: 160,164 148,760 485,501 455,176
Acquisition-related costs 0 (1,896) (228) (2,240)
Restructuring Initiatives (2,208) (2,168) (4,713) (5,789)
Net unrealized investment gain (loss) (1,011) (161) (1,248) 845
Russia deconsolidation impact (61,161) 0 (61,161) 0
Gain from remeasurement of equity method investment 0 26,518 0 26,518
Other special items (3,095) (4,400) (10,899) (4,400)
Depreciation and amortization (75,544) (75,234) (230,910) (210,785)
Interest Expense (15,790) (13,532) (48,733) (35,733)
Interest Income 1,930 2,400 8,359 7,094
Income before Income Taxes 60,333 154,127 269,151 399,856
Provision for CECL     4,374 516
Russia        
Financial information regarding the Company's reportable segments        
Provision for CECL 2,600   2,600  
Legal fees 500   500  
Pharma        
Financial information regarding the Company's reportable segments        
Net Sales 453,970 445,410 1,350,697 1,297,466
Beauty        
Financial information regarding the Company's reportable segments        
Net Sales 357,372 327,768 1,088,461 968,324
Closures        
Financial information regarding the Company's reportable segments        
Net Sales 207,777 187,953 589,337 548,655
Operating Segment        
Financial information regarding the Company's reportable segments        
Net Sales 1,029,567 970,317 3,061,132 2,841,582
Adjusted EBITDA 238,025 235,855 676,883 678,490
Depreciation and amortization (74,437) (74,360) (227,564) (208,236)
Operating Segment | Pharma        
Financial information regarding the Company's reportable segments        
Net Sales 454,194 445,656 1,351,423 1,298,170
Cost of Sales (exclusive of depreciation and amortization): 228,500 221,402 700,573 651,418
Selling, Research & Development and Administrative: 63,322 63,539 196,583 186,725
Other Segment Items: (2,990) (5,300) (11,725) (5,727)
Adjusted EBITDA 165,138 165,769 465,266 465,050
Restructuring Initiatives (406) (919) (345) (1,177)
Depreciation and amortization (35,911) (35,107) (110,814) (100,424)
Operating Segment | Beauty        
Financial information regarding the Company's reportable segments        
Net Sales 365,954 334,929 1,115,538 989,481
Cost of Sales (exclusive of depreciation and amortization): 266,514 243,004 808,864 708,430
Selling, Research & Development and Administrative: 51,025 47,746 156,501 142,896
Other Segment Items: (877) (2,731) (2,838) (6,962)
Adjusted EBITDA 40,710 39,749 125,934 123,960
Restructuring Initiatives (1,827) (550) (4,545) (1,571)
Depreciation and amortization (23,965) (24,332) (73,438) (65,869)
Operating Segment | Closures        
Financial information regarding the Company's reportable segments        
Net Sales 209,419 189,732 594,171 553,931
Cost of Sales (exclusive of depreciation and amortization): 151,847 135,246 430,594 390,999
Selling, Research & Development and Administrative: 25,584 22,895 75,236 69,765
Other Segment Items: (1,831) (525) (2,176) (1,589)
Adjusted EBITDA 32,177 30,337 85,683 89,480
Restructuring Initiatives 25 (702) (311) (2,944)
Depreciation and amortization (14,561) (14,921) (43,312) (41,943)
Intersegment        
Financial information regarding the Company's reportable segments        
Net Sales (10,448) (9,186) (32,637) (27,137)
Intersegment | Pharma        
Financial information regarding the Company's reportable segments        
Net Sales (224) (246) (726) (704)
Intersegment | Beauty        
Financial information regarding the Company's reportable segments        
Net Sales (8,582) (7,161) (27,077) (21,157)
Intersegment | Closures        
Financial information regarding the Company's reportable segments        
Net Sales (1,642) (1,779) (4,834) (5,276)
Corporate & Other        
Financial information regarding the Company's reportable segments        
Adjusted EBITDA (20,813) (13,255) (58,199) (54,144)
Restructuring Initiatives 0 3 488 (97)
Depreciation and amortization $ (1,107) $ (874) $ (3,346) $ (2,549)